Golimumab

BNF:

Musculoskeletal System

Status:

Red

Decision Date:

None

Comments

RED: NICE TA220: psoriatic arthritis (decision date - May 2011)

RED: NICE TA 225: rheumaoid athritis - a recommended option (in the same circumstances as TA130) after other specified treatments have failed or not been tolerated (decision date - July 2011)

RED: NICE TA233: a recommended option for severe, active ankylosing spondylitis in the same circumstances as TA143 when NSAIDs unsuccessful (decision date - Sept 2011)

RED: NICE TA329: recommended option for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (decision date - March 2015)

RED:^1,2,3 NICE TA375 for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (this TA partially replaces TA225) (decision date - Feb 2016)

RED^1,2,3: NICE TA383 for ankylosing spondylitis and non-radiographic axial spondyloarthritis  (decision date - March 2016)

RED^1,2,3: NICE TA497 for treating non-radiographic axial spondyloarthritis (Decision date - February 2018)

CCG commissioned drug.

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again